Author:
Onakpoya Igho J,Heneghan Carl J,Aronson Jeffrey K
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Saf. 1996;15:1–7.
2. Raine J, Wise L, Talbot J, Aronson JK. Proactive pharmacovigilance and risk management. In: Talbot J, Aronson JK, editors. Stephens’ Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th ed. Oxford: Wiley-Blackwell; 2011. p. 389–409.
3. Greener M. Drug safety on trial. Last year’s withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval. EMBO Rep. 2005;6:202–4.
4. European Commission. A Guideline on Summary of Product Characteristics (SmPC). September 2009. http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf . [Accessed 20th March, 2014].
5. Aronson JK. Drug withdrawals because of adverse effects. In: Side Effects of Drugs Annual 30, vol. 30. Amsterdam: Elsevier; 2008. p. xxxi–v.
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献